



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Individualizing Risk Prediction for Positive COVID-19 Testing

Results from 11,672 Patients

¹² ^{Q23} Lara Jehi, MD; Xinge Ji, MS; Alex Milinovich, MS; Serpil Erzurum, MD; Brian Rubin, MD, PhD; Steve Gordon, MD;
¹³ ^{Q1} James Young, MD; and Michael W. Kattan, PhD

BACKGROUND: Coronavirus disease-2019 (COVID-19) is sweeping the globe. Despite multiple case-series, actionable knowledge to tailor decision-making proactively is missing.

RESEARCH QUESTION: Can a statistical model accurately predict infection with COVID-19?

STUDY DESIGN AND METHODS: We developed a prospective registry of all patients tested for COVID-19 in Cleveland Clinic to create individualized risk prediction models. We focus here on the likelihood of a positive nasal or oropharyngeal COVID-19 test. A least absolute shrinkage and selection operator logistic regression algorithm was constructed that removed variables that were not contributing to the model's cross-validated concordance index. After external validation in a temporally and geographically distinct cohort, the statistical prediction model was illustrated as a nomogram and deployed in an online risk calculator.

RESULTS: In the development cohort, 11,672 patients fulfilled study criteria, including 818 patients (7.0%) who tested positive for COVID-19; in the validation cohort, 2295 patients fulfilled criteria, including 290 patients who tested positive for COVID-19. Male, African American, older patients, and those with known COVID-19 exposure were at higher risk of being positive for COVID-19. Risk was reduced in those who had pneumococcal polysaccharide or influenza vaccine or who were on melatonin, paroxetine, or carvedilol. Our model had favorable discrimination (c -statistic = 0.863 in the development cohort and 0.840 in the validation cohort) and calibration. We present sensitivity, specificity, negative predictive value, and positive predictive value at different prediction cutoff points. The calculator is freely available at <https://riskcalc.org/COVID19>.

INTERPRETATION: Prediction of a COVID-19 positive test is possible and could help direct health care resources. We demonstrate relevance of age, race, sex, and socioeconomic characteristics in COVID-19 susceptibility and suggest a potential modifying role of certain common vaccinations and drugs that have been identified in drug-repurposing studies.

CHEST 2020; ■(■):■-■ 99

KEY WORDS: COVID-19; infectious disease; predictive modeling; testing

ABBREVIATIONS: ACE2 = angiotensin converting enzyme 2; COVID-19 = coronavirus disease-2019; IPA = index of prediction accuracy; LASSO = least absolute shrinkage and selection operator; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

AFFILIATIONS: From the Neurological Institute (Dr Jehi), the Quantitative Health Science Department (Dr Kattan, Ms Ji, and Mr Milinovich), Lerner Research Institute, the Respiratory Institute (Dr Erzurum), the Robert J. Tomsich Pathology and Laboratory Medicine Institute (Dr Rubin), the Infectious Disease Department (Dr Gordon), and Cardiology (Dr Young), Cleveland Clinic, Cleveland, OH.

FUNDING/SUPPORT: This study was funded by the Cleveland Clinic and NIH/NCATS UL1TR002548.

CORRESPONDENCE TO: Lara Jehi, MD, 9500 Euclid Ave, Cleveland, OH 44195; e-mail: jehil@ccf.org

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <https://doi.org/10.1016/j.chest.2020.05.580> 108

The first infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel virus responsible for coronavirus disease 2019 (COVID-19) was reported in the United States on January 21, 2020.¹ Three months later, the US health care system and our society are struggling in an ever-changing environment of social distancing policies and projected utilization requirements, with constantly shifting treatment guidelines. A scientific approach to planning and delivering health care is sorely needed to match our limited resources with the persistently unmet demand. This supply-vs-demand gap is most obvious with diagnostic testing. Plagued with technical and regulatory challenges,² the production of COVID-19 test reagents and tests is lagging behind what is needed to fight a pandemic of this scale. Consequently, most hospitals are limiting testing to symptomatic patients and their own exposed health care workers. This is occurring at a time when experts are calling for expanding testing capabilities beyond symptomatic individuals to better measure the infection's transmissibility, limit the spread by quarantine of those infected, and characterize COVID-19's epidemiologic components.³ Recent loosening of the Food and Drug Administration testing

regulations and the development of point-of-care testing will make more tests available; however, given the anticipated demand, it is unlikely that testing supply will be enough. Even if enough testing supplies become available, indications driven by scientific data are still needed. Another challenge is the suboptimal diagnostic performance of the test,⁴ which raises concerns about false-negative results complicating efforts to contain the pandemic. Unless we develop intelligent targeting of our testing capabilities, we will be handicapped significantly in our ability to make progress in assessing the extent of the disease, directing clinical care, and ultimately controlling COVID-19.

We developed a prospective registry aligning data collection for research with clinical care of all patients who are tested for COVID-19 in our integrated health system. We present here the first analysis of our Cleveland Clinic COVID-19 Registry, with the aim to develop and validate a statistical prediction model to guide utilization of this scarce resource by predicting an individualized risk of a "positive test." A nomogram is a visual statistical tool that can take into account numerous variables to predict an outcome of interest for a patient.⁵

Methods

Patient selection

We included all patients, regardless of age, who were tested for COVID-19 at all Cleveland Clinic locations in Ohio and Florida. Albeit imperfect, this provides better representation of the population than testing restricted to the Cleveland Clinic main campus. The Cleveland Clinic Institutional Review Board approval was obtained concurrently with the initiation of testing capabilities (IRB#20-283). The requirement for written informed consent was waived.

Cleveland Clinic COVID-19 Registry

Demographics, comorbidities, travel, and COVID-19 exposure history, medications, presenting symptoms, treatment, and disease outcomes are collected (*e-Appendix 1*). Registry variables were chosen to reflect available literature on COVID-19 disease characterization, progression, and proposed treatments, including medications proposed to have potential benefits through drug-repurposing studies.⁶

Capture of detailed research data is facilitated by the creation of standardized clinical templates that are implemented across the health care system as patients were seeking care for COVID-19-related concerns.

Data were extracted via previously validated automated feeds⁷ from our electronic health record (EPIC; EPIC Systems Corporation, Madison, WI) and manually by a study team trained on uniform sources for the study variables. Study data were collected and managed with the use of Research Electronic Data Capture

(REDCap; Vanderbilt University, Nashville, TN) electronic data capture tools hosted at Cleveland Clinic.^{8,9}

COVID-19 testing protocols

The clinical framework for our testing practice is shown in *Figure 1*. As testing demand increased, we adapted our organizational policies and protocols to reconcile demand with patient and caregiver safety. This occurred in three phases.

Phase I (March 12-13, 2020): We expanded primary care through telemedicine. If patients called for concerns that they had COVID-19, they were screened through a virtual visit with the use of Cleveland Clinic's Express Care Online or called their primary care provider. If they needed to travel to our locations, we asked them to call ahead before arrival. Our goal was to limit exposure to caregivers and to ensure that physicians could order testing when appropriate, while following the Center for Disease Control testing recommendations. A doctor's order was required for testing.

Phase II (March 14-17, 2020): Drive-through testing was initiated on Saturday March 14. Patients still needed to have a doctor's order for a COVID-19 test, similar to Phase I. Testing guidelines were similar to Phase I. On arrival at the drive-through location, patients stayed in their car, provided their doctor's order, and remained in their car as samples were collected. Patients were tested regardless of their ability to pay and were not charged copays.

Phase III (March 18-onwards): Given high testing demand, low initial testing yield, and backlog of tests awaiting to be processed, there was a shift to testing high-risk patients (*Fig 1*).




Figure 1 – Timeline shows the evolution of clinical framework to COVID test ordering during the first 10 days of testing. The single asterisk indicates that patients were sent to the ED only if they needed evaluation of additional symptoms and not purely to obtain COVID testing. The double asterisk indicates that the guidelines to order COVID testing followed the Centers for Disease Control and Prevention recommendations. The main change in phase III was a better definition of high-risk categories, rather than reliance on “physician discretion.” Of note, only 6.7% were tested in phase I + phase II because of physician discretion alone, so that number was too small to perform any modeling work in that group. COVID = coronavirus 2019; OR = operating room; VV = virtual visit.

Processing of COVID tests

Test samples were obtained through naso- and oropharyngeal swabs; both were collected and pooled for testing. Tests were run with the use of the Centers for Disease Control and Prevention assay using Roche magnapure extraction and ABI 7500 DX PCR machines, as per the standard laboratory testing in our organization.


Statistical methods

Model development: Data from 11,672 patients who were tested before April 2 were used to develop the model (development cohort). Baseline data are presented as median (interquartile range) and number (percentage). Continuous variables were compared with the use of the Mann-Whitney U test, and categoric variables were compared with the use of the chi-square test. A full multivariable logistic model was constructed initially to predict COVID-19 Nasopharyngeal Swab Test Result based on demographics, comorbidities, immunization history, symptoms, travel history, laboratory variables, and medications identified before testing. For modeling purposes, methods of missing value imputation for laboratory variables were compared with the use of median values and values from multivariate imputation by chained equations via the R package mice. Restricted cubic splines with 3 knots were applied to continuous variables to relax the linearity assumption. A least absolute shrinkage and selection operator (LASSO) logistic regression algorithm was performed to retain the most predictive features. A

10-fold cross validation method was applied to find the regularization parameter lambda, which gave the minimum mean cross-validated concordance index. Predictors with nonzero coefficients in the LASSO regression model were chosen for calculating predicted risk.

Model validation: The final model was first internally validated by assessment of the discrimination and calibration with 1000 bootstrap resamples. The LASSO procedure, which included 10-fold cross validation for optimizing lambda, was repeated within each resample. We then validated it in a temporally and geographically distinct cohort of 2295 patients tested at the Cleveland Clinic hospitals in Florida from April 2-16, 2020. This was done to assess the model's stability over time and its generalizability to another geographical region.

Model performance: Discrimination was measured with the concordance index.¹⁰ Calibration was assessed visually by plotting the nomogram predicted probabilities against the observed event proportions. The closer the calibration curve lies along the 45-degree line, the better the calibration. A scaled Brier score (index of prediction accuracy [IPA])¹¹ was also calculated, because this has some advantages over the more popular concordance index. The IPA ranges from -1 to 1, where a value of 0 indicates a useless model, and negative values imply a harmful model. Finally, decision curve analysis was conducted to inform clinicians about the range of threshold probabilities for which the prediction model might be

331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403

	Sensitivity	Specificity	NPV	PPV
Cut-off: 10%	0.803	0.730	0.963	0.301
Recommended cut-off: 12.3%	0.762	0.765	0.957	0.319
Cut-off: 30%	0.483	0.913	0.924	0.444

Figure 2 – Proportion of COVID-19 negative tests being avoided (solid line, true negative rate) vs proportion of COVID-19 positive tests being identified (dashed line, true positive rate) at different nomogram predicted probability cut offs. For example, if a predicted probability of ≥ 0.60 was required before testing, nearly all negative cases would have been avoided, but approximately 95% of positive cases would have been missed. At a cut off of 12.3%, the proportion of negative tests being avoided is equal to the proportion of positive tests being detected (intersection of red and blue lines). The Table below shows the sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) for this cut off of 12.3%. For higher cut offs, we illustrate how sensitivity decreases while specificity increases. NPV = negative predictive value; PPV = positive predictive value. See Figure 1 for the expansion.

of clinical value.¹² We then calculated sensitivity, specificity, positive predictive value, and negative predictive value for different recommended test cutoffs (Fig 2). We adhered to the

TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) checklist for prediction model development.

Results

Patient Characteristics

There were 11,672 patients who presented with symptoms of a respiratory tract infection or with other risk factors for COVID-19 before April 2, 2020, and who underwent testing according to the framework illustrated in Figure 1. The testing yield changed as the selection criteria became stricter (e-Fig 1). Between April 2 and 16, 2020, 2295 patients were tested in Florida (Florida validation cohort). The clinical characteristics of the development cohort and validation cohort are found in Table 1.

Nomogram results

Imputation methods were evaluated with 1000 repeated bootstrapped samples. We found that models based on median imputation appeared to outperform those based on data from multivariate imputation by chained

equations imputation, so median imputation was selected for the basis of the final model. Variables that we looked at that were not found to add value beyond those included in our final model for the prediction of the COVID-19 test result included being a health care worker in Cleveland Clinic, fatigue, sputum production, shortness of breath, diarrhea, and transplantation history. The bootstrap-corrected concordance index in the development cohort was 0.863 (95% CI, 0.852-0.874), and the IPA was 20.9% (95% CI, 18.1%-23.7%). The concordance index in the Florida validation cohort was 0.839 (95% CI, 0.817-0.861), and the IPA was 18.7% (95% CI, 13.6%-23.9%). Figure 3 shows the calibration curves in the development and validation cohorts. In the development cohort, the predicted risk matches observed proportions for low predictions before the model begins to overpredict at high-risk levels. Calibration in the Florida validation cohort is

441 TABLE 1] Baseline Demographic and Clinical Characteristics in 11,672 Patients Who Tested Positive vs Negative to 496
 442 COVID-19 in the Development Cohort in the Cleveland Clinic Health System before April 2, 2020, and a 497
 443 Validation Cohort of 2,295 Patients in the Florida Cleveland Clinic Health System Patients Tested Be- 498
 444 tween April 2 and 16, 2020 499

Variable	Development Cohort			Florida Validation Cohort		
	COVID-19 Negative	COVID-19 Positive	P Value	COVID-19 Negative	COVID-19 Positive	P Value
No.	10,854	818		2005	290	
Physician discretion, No. (%)	773 (99.3)	6 (0.7)	<.001	580 (98.5)	9 (1.5)	<.001
Demographics						
Race, No. (%)			<.001			<.001
Asian	174 (98)	9 (2)		46 (85.2)	8 (14.8)	
Black	2,138 (91.1)	207 (8.9)		209 (79.8)	53 (20.2)	
Other	1,194 (92.1)	102 (7.9)		369 (84.6)	67 (15.4)	
White	7,348 (93.6)	500 (6.4)		1381 (89.5)	162 (10.5)	
Male (%)	4,192 (91.0)	415 (9.0)	<.001	831 (85.8)	138 (14.2)	.055
Ethnicity, No. (%)			<.001			<.001
Hispanic	505 (91.3)	48 (8.7)		529 (81.4)	121 (18.6)	
Non-Hispanic	9,608 (93.2)	697 (6.8)		1383 (89.6)	160 (10.4)	
Unknown	741 (91.0)	73 (9.0)		93 (91.2)	9 (8.8)	
Smoking, No. (%)			<.001			<.001
Current Smoker	1,593 (97.7)	37 (2.3)		67 (91.8)	6 (8.2)	
Former Smoker	2,692 (93.0)	202 (7.0)		366 (81.3)	84 (18.7)	
No	5,141 (92.1)	440 (7.9)		626 (87.4)	90 (12.6)	
Unknown	1,428 (91.1)	139 (8.9)		946 (89.6)	110 (10.4)	
Age, median [IQR], y	46.89	54.23	<.001	56.02	51.60	<.001
Missing: 0.3%	[31.57-62.85]	[38.81-65.94]		[41.95-67.52]	[36.69-63.08]	
Exposure history: Yes, No. (%)						
Exposed to COVID-19 ?	1,510 (94.5)	88 (4.5)	.013	492 (68.5)	226 (31.5)	<.001
Family member with COVID-19?	911 (94.1)	57 (5.9)	.174	467 (68.9)	211 (31.1)	<.001
Presenting symptoms: Yes, No. (%)						
Cough?	2,782 (95.5)	130 (4.5)	<.001	609 (70.8)	251 (29.2)	<.001
Fever?	1,918 (94.6)	110 (5.4)	<.001	532 (69.9)	229 (30.1)	<.001
Fatigue?	1,472 (94.4)	87 (5.6)	<.001	406 (68.4)	188 (31.6)	<.001
Sputum production?	929 (96.0)	38 (4.0)	<.001	343 (68.2)	160 (31.8)	<.001
Flu-like symptoms?	1,813 (94.3)	108 (5.7)	.011	507 (70.7)	210 (29.3)	<.001
Shortness of breath?	1,578 (96.0)	64 (4.0)	<.001	462 (75.5)	150 (24.5)	<.001
Diarrhea?	629 (95.0)	33 (5.0)	.043	347 (69.5)	152 (30.5)	<.001
Loss of appetite?	671 (93.4)	47 (6.6)	.671	343 (67.0)	169 (33.0)	<.001
Vomiting?	536 (97.1)	16 (2.9)	<.001	309 (73.2)	113 (26.8)	<.001
Comorbidities						
BMI, median [IQR], kg/m ²	28.46	29.23	.001	27.60	28.91	.037
Missing: 43.3%	[23.90-33.94]	[25.86-33.78]		[23.49-31.05]	[24.81-33.60]	
COPD/emphysema? Yes, No. (%)	304 (96.2)	12 (3.8)	.031	36 (94.7)	2 (5.3)	.257
Asthma? Yes, No. (%)	2,761 (94.9)	147 (5.1)	<.001	176 (91.7)	16 (8.3)	.078

(Continued)

551 TABLE 1] (Continued)

552 Variable	Development Cohort			Florida Validation Cohort		
	553 COVID-19 554 Negative	555 COVID-19 556 Positive	557 P Value	558 COVID-19 559 Negative	560 COVID-19 561 Positive	562 P Value
563 Diabetes mellitus? Yes, 564 No. (%)	565 2,486 (93.0)	566 188 (7.0)	567 .993	568 224 (86.2)	569 36 (13.8)	570 .6
571 Hypertension? Yes, No. 572 (%)	573 4,324 (92.7)	574 342 (7.3)	575 .283	576 460 (86.3)	577 73 (13.7)	578 .444
579 Coronary artery 580 disease? Yes, No. 581 (%)	582 1,325 (93.6)	583 90 (7.4)	584 .336	585 141 (97.9)	586 3 (2.1)	587 <.001
588 Heart failure? Yes, No. 589 (%)	590 1,170 (94.7)	591 66 (5.3)	592 .018	593 88 (96.7)	594 3 (3.3)	595 .01
596 Cancer? Yes, No. (%)	597 1,616 (93.7)	598 108 (6.8)	599 .208	600 245 (92.8)	601 19 (7.2)	602 .006
603 Transplantation 604 history? Yes, No. 605 (%)	606 190 (96.4)	607 7 (3.6)	608 .046	609 43 (95.6)	610 2 (4.4)	611 .149
612 Multiple sclerosis? Yes, 613 No. (%)	614 96 (91.4)	615 9 (8.6)	616 .661	617 8 (88.9)	618 1 (11.1)	619 1
620 Connective tissue 621 disease? Yes, No. 622 (%)	623 3,505 (94.5)	624 203 (5.5)	625 <.001	626 41 (89.1)	627 5 (10.9)	628 .889
629 Inflammatory bowel 630 disease? Yes, No. 631 (%)	632 943 (95.6)	633 45 (4.4)	634 .002	635 34 (81.0)	636 8 (19.0)	637 .304
638 Immunosuppressive 639 disease? Yes, No. 640 (%)	641 1,557 (94.5)	642 91 (5.5)	643 .012	644 163 (92.6)	645 13 (7.4)	646 .039
647 Vaccination history: Yes, 648 No. (%)	649	650	651	652	653	654
655 Influenza vaccine?	656 5,940 (93.9)	657 384 (6.1)	658 <.001	659 328 (91.6)	660 30 (8.4)	661 .011
663 Pneumococcal 664 polysaccharide 665 vaccine?	666	667	668	669	670	671
672 Laboratory findings on 673 presentation	674	675	676	677	678	679
680 Pretesting platelets, 681 median [IQR], **** 682 Missing: 67.3%	683 245.00 [189.00-304.00]	684 190.00 [154.00-241.50]	685 <.001	686 236.00 [180.00-304.00]	687 213.50 [173.00-286.75]	688 .698
689 Pretesting AST, median 690 [IQR], **** 691 Missing: 72.9%	692 23.00 [17.00-34.00]	693 32.00 [24.25-47.00]	694 <.001	695 22.00 [18.00-34.50]	696 31.00 [21.00-53.25]	697 .146
698 Pretesting BUN, median 699 [IQR], **** 700 Missing: 67.2%	701 15.00 [11.00-23.00]	702 14.00 [10.00-22.00]	703 .099	704 18.00 [13.00-27.25]	705 12.00 [8.25-15.50]	706 .003
707 Pretesting chloride, 708 median [IQR], **** 709 Missing: 67.2 %	710 101.00 [97.00-103.00]	711 99.00 [96.00-102.00]	712 <.001	713 100.00 [96.00-102.00]	714 97.50 [92.75-99.25]	715 .026
716 Pretesting creatinine, 717 median [IQR], **** 718 Missing: 67.2%	719 0.90 [0.71-1.21]	720 1.01 [0.79-1.29]	721 <.001	722 0.94 [0.77-1.45]	723 0.92 [0.87-1.03]	724 .677
725 Pretesting hematocrit, 726 median [IQR], **** 727 Missing: 67.3%	728 39.10 [34.20-43.00]	729 40.60 [37.15-43.85]	730 <.001	731 36.80 [32.20-41.00]	732 38.50 [36.02-43.20]	733 .221

(Continued)

661 TABLE 1] (Continued)

716

Variable	Development Cohort			Florida Validation Cohort		
	COVID-19 Negative	COVID-19 Positive	P Value	COVID-19 Negative	COVID-19 Positive	P Value
Pretesting potassium, median [IQR], ^a •••••	4.00 [3.80-4.40]	4.00 [3.70-4.20]	<.001	4.10 [3.90-4.60]	4.15 [3.90-4.35]	.808
Missing: 67.3%						
Home medications						
Immunosuppressive treatment? Yes (%)	423 (97.2)	12 (2.8)	.001	97 (83.6)	19 (16.4)	.271
Nonsteroidal antiinflammatory drugs? Yes (%)	3,084 (95.1)	162 (5.0)	<.001	156 (94.0)	10 (6.0)	.011
Steroids? Yes (%)	2,317 (95.5)	109 (4.5)	<.001	135 (93.8)	9 (6.2)	.024
Carvedilol? Yes (%)	333 (96.2)	13 (3.8)	.022	27 (100.0)	0	.09
ACE inhibitor? Yes (%)	805 (93.3)	58 (6.7)	.784	60 (89.6)	7 (10.4)	.718
ARB? Yes (%)	585 (91.7)	53 (8.3)	.214	78 (90.7)	8 (9.3)	.434
Melatonin? Yes (%)	513 (97.0)	16 (3.0)	<.001	18 (100.0)	0	.206
Social influencers of health						
Population/km ² , ^a median [IQR]	3.06 [2.69-3.36]	3.08 [2.72-3.37]	.24	3.20 [3.02-3.35]	3.28 [3.12-3.42]	<.001
Missing: 0.1%						
Median income × \$1000, median [IQR], \$	55.61 [38.73-78.56]	60.46 [42.77-84.24]	<.001	66.28 [53.41-89.11]	59.07 [47.59-75.56]	<.001
Missing: 0.1%						
Population per housing unit, median [IQR], No.	2.21 [1.88-2.56]	2.25 [1.89-2.59]	.038	2.47 [1.83-2.87]	2.61 [2.11-2.92]	.001
Missing: 0.1%						

Q20

Q21

ACE = angiotensin converting enzyme; ARB, = •••••; AST = •••••; COVID-19 = coronavirus 2019; IQR = interquartile range.

a•••••.




Figure 3 – Calibration curves for the model predicting likelihood of a positive test. The x-axis displays the predicted probabilities generated by the statistical model, and the y-axis shows the fraction of the patients who were COVID-19 positive at the given predicted probability. The 45-degree line therefore indicates perfect calibration, for example, a predicted probability of 0.2 is associated with an actual observed proportion of 0.2. The solid black line indicates the model's relationship with the outcome. The closer the line is to the 45-degree line, the closer the model's predicted probability is to the actual proportion. A, The calibration curve in the development cohort of 11,672 patients tested in Cleveland Clinic Health System before April 2. B, The calibration curve in the Florida Validation Cohort (2295 patients tested in Cleveland Clinic Florida from April 2-16, 2020). As demonstrated, there is excellent correspondence between the predicted probability of a positive test and the observed frequency of COVID-19 positive in both cohorts. See Figure 1 legend for the expansion of abbreviations.

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013


1014

1015

1016

1017

1018

Figure 4 – The graphic version of the model (A) and the corresponding online risk calculator (B).¹³

(Continued on next page)

771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880




Figure 4 – Continued. The example for both is a 60-year-old white male, former smoker, who presented with cough, fever, and a history of a known family member with COVID-19. He has coronary artery disease, did not receive vaccinations against influenza or pneumococcal pneumonia this year, and is only on melatonin to help with sleep. No laboratory tests were performed at the time of COVID-19 testing. His predicted risk of testing positive is 13.79%. If race is changed to black, with all other variables remaining constant, his relative risk almost doubles to an absolute value of 23.95%. ACE = angiotensin converting enzyme; ARB = ••••; AST = ••••; NSAIDS = nonsteroidal antiinflammatory drugs. See Figure 1 for expansion of other abbreviation.

acceptable, although predictions >40% become too high as the predicted probability increases.

Cut Off Definition

Given that the tool provides a probability that an individual subject will test positive, the challenge is to use the tool in practice. This usually would require choosing a cut off below which the risk is sufficiently low that the subject would not be tested. Figure 2 shows the tradeoff by plotting the proportion of negative tests avoided vs the proportion of positive tests retained as the cut off is increased. A decision curve analysis showed that, if the threshold of action is $\leq 1.3\%$, the model is not better than simply assuming everyone is “high risk.” However, once the threshold becomes $>1.3\%$, using the model to determine who is high risk is preferable. The nomogram and its online version are shown in Figure 4.¹³

Discussion

The COVID-19 pandemic has impacted the world significantly, changing medical practice and our society. Some countries are now recovering from it, but many regions are just beginning to be affected. In the United States, some states are still preparing for a “surge” that

may overwhelm the health care delivery system, while others are preparing to “reopen” and lift social distancing measures. In a “presurge” situation, resources needed to address every step of a patient’s trajectory through COVID-19 are limited, starting from testing through hospitalization and intensive care if needed. In a “pre-reopening” situation, tools to better identify individuals who are at risk of experiencing COVID-19 are sorely needed to inform policy.

We developed the Cleveland Clinic COVID-19 Registry to include all patients who were tested for COVID-19 (rather than just those with the disease) to better understand disease epidemiology and to develop nomograms, which are tools that go beyond cohort descriptions to individualize risk prediction for any given patient. This could empower front-line health care providers and inform decision-making, immediately impacting clinical care. We present here our first such nomogram, one that predicts the risk of a positive COVID-19 test. We want to emphasize that our work should not be interpreted as “accepting” or rationalizing inadequate testing capacity. Our tool should not take the pressure off being able to do what is right clinically for individual patients by expanding testing capabilities.

991 COVID-19 Testing Challenge

Available COVID-19 clinical literature is based mostly on small case series or descriptive cohort studies of patients already documented to have COVID-19¹⁴⁻²³: this provides some information on the population that may be at greatest risk of adverse outcomes if they get infected with the virus but does little to inform us on who is most at risk to get infected. The proportion of COVID negative tests fell significantly in the patient population with stricter testing guidelines ([e-Fig 1](#)), but the yield remained very low, which suggests that our ability to differentiate COVID-19 clinically from other respiratory illnesses at the early stages of the disease is limited, further supporting the need for better tools to individualize testing indications.

1009 COVID-19 Risk Factors

Some of our predictors for developing COVID confirm previous literature. For example, we corroborate a recent World Health Organization report that suggests that men may be at higher risk of experiencing COVID-19,²⁴ which is thought to reflect underlying hormonal or genetic risk. Our finding of a higher COVID-19 risk with advancing age can be explained by known age-related changes in the angiotensin-renin system in mice²⁵ and humans²⁶ that may facilitate infection with the SARS-CoV-2 virus, which binds to the host cells through angiotensin receptors. A family member with COVID-19 also increased the risk of testing positive in our cohort, which is consistent with familial disease clustering observed in China and highlights the limitations of disease containment strategies that focus on home lock-down without isolation of sick individuals. In addition, our study provides several unique insights that are made possible by our large sample size and our inclusion of a control cohort of patients who tested negative for COVID. The following list includes critical findings that ultimately were relevant to our model's performance.

- 1035 (1) The lower risk of being COVID positive in Asian
1036 individuals relative to white individuals in our
1037 cohort is intriguing, given the higher rates of spread
1038 and disease severity that were observed in the
1039 western hemisphere now when compared with
1040 China.

1041 (2) The lower risk observed with pneumococcal poly-
1042 saccharide vaccine and flu vaccine is also a unique
1043 finding. The mechanism could be biologic, related
1044 possibly to the documented sustained activation of

Toll-Like Receptor 7 by the influenza vaccine²⁷:
Toll-Like Receptor 7 is critical for the binding of
single-stranded RNA respiratory viruses, such as
SARS-CoV-2, and may thus explain some cross
protection. Alternatively, this correlation may just
reflect safer health practices in general of people who
seek and obtain vaccination.

- (3) The higher risk observed with poor socioeconomic status. Using the zip code, our team was able to infer estimated population per square kilometer and estimated median income from the 5-year American Community Survey dataset. The end year of the 5-year dataset was 2018. The critical role played by these variables in our final model emphasize the importance of social influencers of health and their influence on disparities in health care outcomes.

(4) Most potentially impactful is the reduced risk of testing positive in patients who were on melatonin, carvedilol, and paroxetine, which are drugs identified in drug-repurposing studies to have a potential benefit against COVID-19.⁶ Melatonin up-regulates angiotensin converting enzyme 2 (ACE2) expression, such that increased occupancy of ACE2 receptors competes with SARS-CoV2 viral attachment to the receptors and blocks entry.⁶ Carvedilol was found recently to inhibit ACE2-induced proliferation and contraction in hepatic stellate cells through the rhoa/rho-kinase pathway.²⁸ It is unclear whether it has similar effects on ACE2 in lung endothelium. With ACE2 being key in the pathophysiologic findings of infection with SARS-CoV-2, our findings are intriguing.

These findings would have to be reproduced and validated in clinical trials before their full significance can be assessed. When interpreting our multivariable model, it is important to recognize that a single predictor cannot be interpreted in isolation. For example, it is artificial to claim that a drug is reducing risk because, in reality, other variables tend to be different for a patient who is on, or not on, a drug. Moving a patient on a nomogram axis, holding all other axes constant, is hypothetical, because he or she is likely moving on other axes when moved on one. This is the case for all multivariable statistical prediction models.

Nomogram Performance

Model performance, as measured by the concordance index, is very good in the development and in the validation cohort (c -statistic = 0.863 and 0.839, respectively). This level of discrimination is clearly

superior to a coin toss or assuming all patients are at equivalent risk (both c-statistics = 0.5). The internal calibration of the model is excellent at low predicted probabilities (Fig 3), but some regression to the mean is apparent at predictions >40% or so in the validation cohort. This would seem to be of little concern, that the model is overpredicting risk at that level, because this is considerably high risk clinically and likely beyond a threshold of action. Moreover, the metric that considers calibration, the IPA value, confirms that the model predicts better than chance or no model at all. The good performance of our model in a geographically distinct region (Florida), and over time (validation cohort in patients tested at a later timeframe) suggests that patterns and predictors identified in our model are likely consistent across health systems and regions, rather than specific to the unique spread of the virus within Cleveland's social structures.

Clinical Utility

As with any predictive tool, the utility of a nomogram depends on the clinical context. The decision curve analysis suggests that, if the goal is to distinguish patients with a risk of 1.3% (or a higher cut off) vs those of higher risk, then the prediction model is useful. In other words, using the model to determine whom to test detects more true positives per test performed than does testing everyone as long as one is willing to test 1000 subjects to detect 13 cases. Any cut off choice involves tradeoffs of avoiding negative tests vs missing positive cases (Fig 2). Using a low prediction cut off (<1.3% from the tool) as a trigger to order testing will allow us to continue to identify a vast majority of COVID positive cases (assuming we maintain our other selection criteria for testing constant) while avoiding testing a large proportion of patients who are indeed COVID negative. This may be appropriate when testing supplies are abundant and one wants to comprehensively survey the extent of COVID-19 in the population. Conversely, in a resource-limited setting (eg, hospital facing a surge), a cut off $\geq 1.3\%$ may be more appropriate to avoid unnecessary testing.

Study Limitations

Available real-time reverse transcriptase polymerase chain reaction tests of nasopharyngeal swabs have been used typically for diagnosis, but data suggest suboptimal test performance because it detected only the SARS-CoV-2 virus in 63% of nasal swabs and 32% of pharyngeal swabs in patients with known disease.⁴ In our study, we did both swabs, hoping to at least partly address this limitation. Although we performed validation of our model in a temporally and geographically distinct cohort, we acknowledge the fact that our results depend on the particular time and place that the data were collected. As the pandemic evolves, our results may not reflect updated distribution of the virus in any given region, and our model will need to be refit. To accommodate an ever-increasing COVID-19 prevalence, the model will need to be recalibrated and refit over time. Our online risk calculator is publicly available, but direct integration with the electronic health record can further improve its utility. The online calculator will reflect this updating. Our study is not designed to evaluate the very real issue of health care disparities, which would require a population-based approach for the study of health care delivery that is beyond the scope of the work presented here. Our conclusions are highly dependent on access to testing sites and doctors' orders rather than population-based predictors of positive results.

Interpretation

We provide an online risk calculator that effectively can identify individualized risk of a positive COVID-19 test. Such a tool provides immediate benefit to the patients and health care providers as we face anticipated increased demand and limited resources but does not obviate the critical need for adequate testing. The scarcity of resources must not be accepted as an unalterable fact, and we should resist the inevitability of lack of resources and inequities in health care. We also provide some mechanistic and therapeutic insights.

1211 Acknowledgments

1212 **Author contributions:** L. J. is the guarantor
 1213 of submission and participated in literature
 1214 search, figures, study design, data collection,
 1215 data interpretation, and writing; X. J.
 1216 participated in data analysis and figures; A.
 1217 M. participated in data collection and data
 1218 analysis; S. E. participated in data
 1219 interpretation, study design, and writing; B.
 1220 R., S. G., and J. Y. participated in data
 1221 interpretation and writing; and M. W. K.
 1222 participated in literature search, study design,
 1223 data interpretation, data analysis, and
 1224 writing.

1225 **Financial/nonfinancial disclosures:** The
 1226 authors have reported to CHEST the
 1227 following: A. M. reports personal fees from
 1228 nPhase, during the conduct of the study;
 1229 grants from Novo Nordisk, grants from
 1230 Boehringer Ingelheim, grants from Merck,
 1231 grants from Novartis, grants from NIH,
 1232 outside the submitted work. M. W. K. reports
 1233 personal fees from nPhase, during the
 1234 conduct of the study; grants from Novo
 1235 Nordisk, grants from Boehringer Ingelheim,
 1236 grants from Merck, grants from Novartis,
 1237 grants from NIH, consulting for Stratify
 1238 Genomics and RenalyxAI outside the
 1239 submitted work. None declared (L. J., X. J., S.
 1240 E., B. R., S. G., J. Y.).

1241 **Role of sponsors:** The sponsor had no role in
 1242 the design of the study, the collection and
 1243 analysis of the data, or the preparation of the
 1244 manuscript.

1245 **Additional information:** The e-Appendix
 1246 and e-Figure can be found in the
 1247 Supplemental Materials section of the online
 1248 article.

1249 References

1. Callaway E, Cyranoski D, Mallapaty S, Stoye E, Tollefson J. The coronavirus pandemic in five powerful charts. *Nature* March 18, 2020. <https://www.nature.com/articles/d41586-020-00758-2>. Accessed on March 21, 2020.
2. Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the novel coronavirus. *JAMA*. In press.
3. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19 -studies needed. *N Engl J Med*. In press.
4. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. In press.
5. Kattan MW. Nomograms: introduction. *Semin Urol Oncol*. 2002;20(2):79-81.
6. Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov*. 2020;6:14.
7. Milinovich A, Kattan MW. Extracting and utilizing electronic health data from Epic for research. *Ann Transl Med*. 2018;6(3):42.
8. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381.
9. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software partners, *J Biomed Inform*. In press.
10. Harrell FE Jr, Calif RM, Pryor B, Lee KL, Rosati RA. Evaluating the yield of medical tests. *JAMA*. 1982;247(18):2543-2546.
11. Kattan MW, Gerd TA. The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models. *Diagn Progn Res*. 2018;2:7.
12. Steyerberg E, Vickers A, Cook N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21(1):128-138.
13. Cleveland Clinic. Predict COVID-19 test result. <https://riskcalc.org/COVID19/>. Accessed.
14. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. In press.
15. Sun Y, Koh V, Marimuthu K, et al. Epidemiological and clinical predictors of COVID-19. *Clin Infect Dis*. In press.
16. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet*. In press.
17. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care*. 2020;24:108.
18. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with
- coronavirus disease 2019 in Wuhan, China. *Clin Infect Dis*. In press. 1266
19. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. In press. 1267
20. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. In press. 1268
21. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. In press. 1269
22. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. In press. 1270
23. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. 1271
24. ••••. ••••. <http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/weekly-surveillance-report>. Accessed March 28, 2020. 1272
25. Yoon HE, Kim EN, Kim MY, et al. Age-associated changes in the vascular renin-angiotensin system in mice. *Oxide Med Cell Longev*. 2016;2016:6731093. 1273
26. Ogbadu J, Singh G, Gupta K, Mehra K, Sen P. Ageing reduces angiotensin II type 1 receptor antagonism mediated pre-conditioning effects in ischemic kidneys by inducing oxidative and inflammatory stress. *Exp Gerontol*. 2020;135:110892. 1274
27. Goff PH, Hayashi T, Martínez-Gil L, et al. Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. *J Virol*. 2015;89(6):3221-3235. 1275
28. Wu Y, Li Z, Wang S, Xiu A, Zhang C. Carvedilol inhibits angiotensin ii-induced proliferation and contraction in hepatic stellate cells through the RhoA/Rho-Kinase pathway. *Biomed Res Int*. 2019;2019:7932046. 1276